Mar 04, 2019 - Top Research Reports for Intel, AbbVie & United Technologies
Mar 04, 2019 - AbbVie (ABBV) gets positive opinion of the CHMP recommending marketing approval for risankizumab for the treatment of moderate-to-severe plaque psoriasis.
Feb 27, 2019 - A Senate committee roasted top executives of the biggest drugmakers. But will anything change for ordinary Americans?
Feb 26, 2019 - Top drug companies addressed sky-high drug prices on Capitol Hill today.
Feb 25, 2019 - Momenta (MNTA) reported a narrower loss in Q4, while sales came ahead of expectations.
Feb 22, 2019 - Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).
Feb 19, 2019 - The FDA accepts Roche's (RHHBY) BLA for polatuzumab vedotin and NDAs for entrectinib, and grants Priority Review status to the applications.
Feb 16, 2019 - Twitter, ExxonMobil, and Abbvie are companies you need to look at today.
Feb 12, 2019 - AbbVie (ABBV) enters a global strategic transaction agreement with privately-held Teneobio to develop and commercialize the latter's pre-clinical immunotherapy candidate, TNB-383B, as a multiple myeloma treatment.
Feb 11, 2019 - The company secured a deal paving the way to commercialize a generic version of the former best-selling drug in the world.